Payment overview · 2025
General Payments
$411.94
17 reported records · 6 companies
Healthcare provider profile · identity verified
Ester Rose Hare, MD.PHD.FACP
Allopathic & Osteopathic Physicians|Internal Medicine · ORANGEBURG, SC · NPI 1538144795
Verified facts
What the public records show
CMS Open Payments records show Ester Rose Hare, MD.PHD.FACP received $411.94 in general payments during 2025 across 17 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $159.51 | 38.7% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.42 | 27.3% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $70.85 | 17.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.44 | 7.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.46 | 5.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.26 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $411.94 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $159.51 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.42 | 4 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $40.70 | 1 | 2025 |
Source payment records
|
|||||
| XENPOZYME Normalized: xenpozyme |
Biological | GENZYME CORPORATION | $30.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 205 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 577 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 466 | 136 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 116 |
| Metformin Hcl Er | Metformin Hcl | 262 | 79 |
| Jardiance | Empagliflozin | 205 | 45 |
| Mounjaro | Tirzepatide | 203 | 39 |
| Glipizide Er | Glipizide | 176 | 60 |
| Furosemide | Furosemide | 172 | 62 |
| Montelukast Sodium | Montelukast Sodium | 171 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 161 | 43 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 160 | 43 |
| Gabapentin | Gabapentin | 152 | 50 |
| Meloxicam | Meloxicam | 152 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 134 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 39 |
| Nifedipine Er | Nifedipine | 132 | 37 |
| Omeprazole | Omeprazole | 123 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 58 |
| Prednisone | Prednisone | 115 | 77 |
| Donepezil Hcl | Donepezil Hcl | 112 | 26 |
| Famotidine | Famotidine | 112 | 32 |
| Simvastatin | Simvastatin | 111 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 32 |
| Potassium Chloride | Potassium Chloride | 107 | 29 |
| Losartan Potassium | Losartan Potassium | 105 | 30 |
| Eliquis | Apixaban | 96 | 17 |
| Mirtazapine | Mirtazapine | 96 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 61 |
| Alprazolam | Alprazolam | 87 | 23 |
| Azithromycin | Azithromycin | 87 | 57 |
| Colchicine | Colchicine | 81 | 25 |
| Alendronate Sodium | Alendronate Sodium | 75 | 21 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 73 | 21 |
| Ibuprofen | Ibuprofen | 72 | 33 |
| Tramadol Hcl | Tramadol Hcl | 68 | 18 |
| Pregabalin | Pregabalin | 64 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 19 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 61 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 61 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 13 |
| Farxiga | Dapagliflozin Propanediol | 54 | 12 |
| Fluconazole | Fluconazole | 54 | 35 |
| Lisinopril | Lisinopril | 54 | 17 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 52 | 16 |
| Carvedilol | Carvedilol | 52 | 16 |
| Meclizine Hcl | Meclizine Hcl | 51 | 19 |
| Mupirocin | Mupirocin | 51 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 31 |
| Ezetimibe | Ezetimibe | 49 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 21 |
| Clonidine Hcl | Clonidine Hcl | 46 | 15 |
| Metformin Hcl | Metformin Hcl | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | 14 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 28 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 14 |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | 11 |
| Linzess | Linaclotide | 37 | 12 |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | 16 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 13 |
| Ondansetron Odt | Ondansetron | 19 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Mitigare | Colchicine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $411.94 · 17 records | Bayer Healthcare Pharmaceuticals Inc. | FABRAZYME, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, XENPOZYME, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error